Education
About Us
Working with TipRanks
Follow Us
Myriad Genetics (MYGN)
NASDAQ:MYGN
MYGN Stock Chart & Stats
$5.15
$0.24(1.68%)
At close: 4:00 PM EST
$5.15
$0.24(1.68%)
Day’s Range― - ―
52-Week Range$3.76 - $11.44
Previous CloseN/A
Volume154.82K
Average Volume (3M)1.34M
Market Cap
$481.57M
Enterprise Value$541.77M
Total Cash (Recent Filing)$149.60M
Total Debt (Recent Filing)$209.80M
Price to Earnings (P/E)―
Beta1.60
Next Earnings
Apr 30, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.04
Shares Outstanding93,508,160
10 Day Avg. Volume2,252,075
30 Day Avg. Volume1,344,087
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.56
Price to Sales (P/S)0.70
P/FCF Ratio318.77
Enterprise Value/Market Cap1.13
Enterprise Value/Revenue0.66
Enterprise Value/Gross Profit0.94
Enterprise Value/Ebitda-1.36
Forecast
1Y Price Target
$6.58Price Target Upside27.77% Upside
Rating ConsensusHold
Number of Analyst Covering8
EPS Forecast (FY)0.05
Revenue Forecast (FY)$864.32M
Bulls Say, Bears Say
Bulls Say
Guidance And Growth OutlookCompany guidance indicates a modest acceleration in growth, implying improving revenue momentum across the business.
Product Volume GrowthVolume gains in key product lines such as HCT, GeneSight, and Prolaris suggest diversification of revenue drivers and potential top-line uplift.
Quarterly ResultsQuarterly results modestly exceeded preannouncement and consensus estimates, signaling stronger-than-expected demand in core diagnostic tests.
Bears Say
Execution Risk And Competitive PressureAnalyst reiterates that sustained growth depends on successful execution in a crowded advanced molecular diagnostics market, raising concerns about market share expansion.
Pipeline Timing And Guidance ExclusionManagement's guidance excludes potential contribution from molecular residual disease testing, indicating that expected upside from this diagnostic may arrive later than current targets and add execution risk.
Reimbursement UncertaintyUncertainty around reimbursement for newly launched tests may force selective acceptance of volumes and constrain near-term revenue growth.
Myriad Genetics News
MYGN FAQ
What was Myriad Genetics’s price range in the past 12 months?
Myriad Genetics lowest stock price was $3.76 and its highest was $11.44 in the past 12 months.
What is Myriad Genetics’s market cap?
Myriad Genetics’s market cap is $481.57M.
When is Myriad Genetics’s upcoming earnings report date?
Myriad Genetics’s upcoming earnings report date is Apr 30, 2026 which is in 52 days.
How were Myriad Genetics’s earnings last quarter?
Myriad Genetics released its earnings results on Feb 23, 2026. The company reported $0.04 earnings per share for the quarter, beating the consensus estimate of -$0.015 by $0.055.
Is Myriad Genetics overvalued?
According to Wall Street analysts Myriad Genetics’s price is currently Undervalued.
Does Myriad Genetics pay dividends?
Myriad Genetics pays a Monthly dividend of $1.75 which represents an annual dividend yield of N/A. See more information on Myriad Genetics dividends here
What is Myriad Genetics’s EPS estimate?
Myriad Genetics’s EPS estimate is -0.07.
How many shares outstanding does Myriad Genetics have?
Myriad Genetics has 93,508,160 shares outstanding.
What happened to Myriad Genetics’s price movement after its last earnings report?
Myriad Genetics reported an EPS of $0.04 in its last earnings report, beating expectations of -$0.015. Following the earnings report the stock price went up 1.142%.
Which hedge fund is a major shareholder of Myriad Genetics?
Currently, no hedge funds are holding shares in MYGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Myriad Genetics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$6.58 (27.77% Upside)
$6.58 (27.77% Upside)
Blogger Sentiment
Bullish
MYGN Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 106.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $494.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 4.3%
Last 30 Days ▼ 4.3%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-51.04%
12-Months-Change
Fundamentals
Return on Equity
-68.45%
Trailing 12-Months
Asset Growth
-31.24%
Trailing 12-Months
Company Description
Myriad Genetics
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. In addition, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics for an offering of germline and somatic tumor testing services. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
MYGN Company Deck
MYGN Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed clear operational momentum: revenue above guidance in Q4, accelerating volumes in key products (MyRisk, Prolaris, GeneSight), profitable Q4 results and strong cash generation, plus a robust product pipeline and reaffirmed 2026 guidance. Key challenges include a material UnitedHealthcare headwind for GeneSight, prenatal order-system disruption and near-term reimbursement uncertainty for MRD; management presented concrete mitigation actions, cautious commercialization plans for MRD, and targeted investments to accelerate growth. On balance, the positive operational and product-development progress and reaffirmed guidance outweigh the identifiable near-term headwinds.View all MYGN earnings summariesMYGN Stock 12 Month Forecast
Average Price Target
$6.58
▲(27.77% Upside)
Technical Analysis
Ownership Overview
4.56% Insiders
16.57% Mutual Funds
7.10% Other Institutional Investors
45.71% Public Companies and
Individual Investors